EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual targeting of the androgen receptor and PI3K / AKT / mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis

Tatsuo Sugawara, Ekaterina Nevedomskaya, Simon Heller, Annika Böhme, Ralf Lesche, Oliver von Ahsen, Sylvia Grünewald, Holly M Nguyen, Eva Corey, Simon J Baumgart, Victoria Georgi, Vera Pütter und 6 weitere

Molecular Oncology · 2024-03 · 18 (3) · 726-742

DOI: 10.1002/1878-0261.13577 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 15.01.2024. Verfasst von Tatsuo Sugawara und 17 weiteren Autor:innen. Beteiligte Einrichtung: Bayer AG, Pharmaceuticals, Research & Early Development Oncology, Berlin, Germany. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Prostatic Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer is a frequent malignancy in older men and has a very high 5‐year survival rate if diagnosed early. The prognosis is much less promising if the tumor has already spread outside the prostate gland. Targeted treatments mainly aim at blocking androgen receptor (AR) signaling and initially show good efficacy. However, tumor progression due to AR‐dependent and AR‐independent mechanisms is often observed after some time, and novel treatment strategies are urgently needed. Dysregulation of the PI3K/AKT/mTOR pathway in advanced prostate cancer and its implication in treatment resistance has been reported. We compared the impact of PI3K/AKT/mTOR pathway inhibitors with different selectivity profiles on in vitro cell proliferation and on caspase 3/7 activation as a marker for apoptosis induction, and observed the strongest effects in the androgen‐sensitive prostate cancer cell lines VCaP and LNCaP. Combination treatment with the AR inhibitor darolutamide led to enhanced apoptosis in these cell lines, the effects being most pronounced upon cotreatment with the pan‐PI3K inhibitor copanlisib. A subsequent transcriptomic analysis performed in VCaP cells revealed that combining darolutamide with copanlisib impacted gene expression much more than individual treatment. A comprehensive reversal of the androgen response and the mTORC1 transcriptional programs as well as a marked induction of DNA damage was observed. Next, an in vivo efficacy study was performed using the androgen‐sensitive patient‐derived prostate cancer (PDX) model LuCaP 35 and a superior efficacy was observed after the combined treatment with copanlisib and darolutamide. Importantly, immunohistochemistry analysis of these treated tumors showed increased apoptosis, as revealed by elevated levels of cleaved caspase 3 and Bcl‐2‐binding component 3 (BBC3). In conclusion, these data demonstrate that concurrent blockade of the PI3K/AKT/mTOR and AR pathways has superior antitumor efficacy and induces apoptosis in androgen‐sensitive prostate cancer cell lines and PDX models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-aktProstatic NeoplasmsMaleHumansAgedReceptors, AndrogenPhosphatidylinositol 3-KinasesCaspase 3AndrogensTOR Serine-Threonine KinasesCell ProliferationApoptosisCell Line, Tumor

Stichwörter der Autor:innen

PI3 kinaseProstateandrogen receptor

Substanzen

Proto-Oncogene Proteins c-aktReceptors, AndrogenPhosphatidylinositol 3-KinasesCaspase 3AndrogensTOR Serine-Threonine Kinases

Autor:innen und Institutionen

  • Bayer AG, Pharmaceuticals, Research & Early Development Oncology, Berlin, Germany.
  • Nuvisan ICB GmbH, Berlin, Germany.
  • Department of Urology, University of Washington, Seattle, WA, USA.
  • Promega Corporation, Madison, WI, USA.

ORCID-Profile: Bernard Haendler

Zitieren

APA

Sugawara, T., Nevedomskaya, E., Heller, S., Böhme, A., Lesche, R., von Ahsen, O., Grünewald, S., Nguyen, H. M., Corey, E., Baumgart, S. J., Georgi, V., Pütter, V., Fernández-Montalván, A., Vasta, J. D., Robers, M. B., Politz, O., Mumberg, D., & Haendler, B. (2024). Dual targeting of the androgen receptor and PI3K / AKT / mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis. Molecular Oncology, 18(3), 726-742. https://doi.org/10.1002/1878-0261.13577

Vancouver

Sugawara T, Nevedomskaya E, Heller S, Böhme A, Lesche R, von Ahsen O, et al. Dual targeting of the androgen receptor and PI3K / AKT / mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis. Molecular Oncology. 2024;18(3):726-742. doi:10.1002/1878-0261.13577

BibTeX
@article{Sugawara2024,
  author = {Sugawara, Tatsuo and Nevedomskaya, Ekaterina and Heller, Simon and Böhme, Annika and Lesche, Ralf and von Ahsen, Oliver and Grünewald, Sylvia and Nguyen, Holly M and Corey, Eva and Baumgart, Simon J and Georgi, Victoria and Pütter, Vera and Fernández-Montalván, Amaury and Vasta, James D and Robers, Matthew B and Politz, Oliver and Mumberg, Dominik and Haendler, Bernard},
  title = {Dual targeting of the androgen receptor and PI3K / AKT / mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis},
  journal = {Molecular Oncology},
  year = {2024},
  volume = {18},
  number = {3},
  pages = {726--742},
  doi = {10.1002/1878-0261.13577}
}
Kostenlos starten →